

ondine



For Immediate Release

**Ondine's Periowave™ Product approved for Additional Indications in
European Union**

- Peri-implantitis and Endodontic Applications -

Vancouver, Canada – June 28th, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that the European Commission has approved its Periowave™ Photodisinfection System for the treatment of dental peri-implant disease as well as for endodontic disinfection. The European Commission decision applies to all 27 countries in the European Union as well as Iceland and Norway. These additional indications build upon the previously approved Periowave™ indication for the treatment of periodontal disease. In addition to the European Union, Periowave™ is currently approved and marketed in Canada.

“We are pleased to be able to report on the review and approval by European regulatory authorities of these expanded indications,” stated Carolyn Cross, President and CEO of Ondine. “European dental practitioners are now equipped with a novel, alternative therapeutic option in the treatment of the complex, polymicrobial infections that often characterize intra-oral diseases such as peri-implantitis and periodontitis. Over time, our goal is to provide the dental clinic with the leading, one-stop disinfection technology to satisfy all therapeutic and prophylactic disinfection requirements. Meanwhile in the US, we expect to submit our application shortly for the gum disease indication to the FDA, building upon our extensive experience with Periowave™ and the numerous satisfied practitioners and patients.”

About Peri-Implant Disease and Endodontics

Peri-implantitis affects 5% to 10% of implant patients and is a form of gum disease caused by bacteria that colonize the tissues surrounding a dental implant. If left untreated, peri-implantitis may lead to loss of the bone structure supporting an implant, a major cause of implant failure. Endodontics is a branch of dentistry concerned with the treatment of the pulp chamber, or root canal, of the tooth. This chamber contains nerves, blood vessels and cells regulating tooth development. Pulp decay is caused by a bacterial invasion of the pulp chamber. If left untreated, this infection may spread from the pulp chamber to tissues surrounding the root, causing further breakdown and severe pain.

About Periowave™ and Photodisinfection

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

For further information please contact:

| | |
|--|--|
| Carolyn Cross | Christina Bessant |
| President and Chief Executive Officer | Investor Relations |
| Ondine Biopharma Corporation | The Equicom Group Inc. |
| (604) 669-0555 | (416) 815-0700 ext. 269 |
| ccross@ondinebiopharma.com | cbessant@equicomgroup.com |